Navigation Links
MicroRNAs, EMT and cancer progression

In the April 1 issue of G&D, a research team led by Dr. Marcus Peter (University of Chicago) identifies the microRNA miR-200 as both a powerful indicator and regulator of the epithelial phenotype of cancer cells.

EMT (the epithelial-to-mesenchymal transition) is the conversion of an epithelial cell into a mesenchymal cell. Morphologically, EMT is characterized by a loss of cell adhesion and increased cell motility. At a molecular level, it is characterized by a decreased expression of the cell adhesion molecule and epithelial marker, E-cadherin, and an increased expression of the intermediate filament protein and mesenchymal cell marker, Vimentin.

EMT is a normal embryological process, but it is implicated in various adult pathologies including cancer metastasis.

Dr. Peter and colleagues analyzed 60 different cell lines from the National Cancer Institute, representing 9 different types of human cancers, and found that miR-200 is a consistent marker of cells that express E-cadherin but lack Vimentin. This was confirmed for primary ovarian cancer.

The researchers went on to show that miR-200 targets the transcriptional repressors of E-cadherin, ZEB1 and ZEB2, and that altering miR-200 levels in established cancer cell lines induced changes consistent with either inducing EMT or the reverse process, MET. Thus, in the context of cancer progression, decreased miR-200 expression increases ZEB1/2 activity, represses E-cadherin levels, and ultimately induces EMT.

"We expected an important process of cellular differentiation such as EMT to be regulated by microRNAs but were surprised by the extraordinarily tight control of EMT by miR-200 through the ZEB proteins. Our ability to reverse EMT by reintroducing miR-200 into cancer cells gives rise to the hope that this miRNA family might be useful in reversing cancer progression" explains Dr. Peter.


Contact: Heather Cosel-Pieper
Cold Spring Harbor Laboratory

Page: 1

Related medicine news :

1. A new way to fight cancer: the silver shield
2. Many Women Unclear About Breast Cancer Treatments
3. You May Be the Key to Cancer Prevention
4. Study finds improvement in the care of children with cancer at the end of life
5. State of Cancer Care for Nations Poor and Minorities Is Focus of Conference in Washington
6. Hit One Out of the Park for the PA Breast Cancer Coalition
7. Saving cancer patients skin
8. Mens Health Policy Center Hosts Petition to Protest Government Barrier to Prostate Cancer Medications
9. Too many women still dying from breast cancer, says charity
10. A Picture Perfect Partnership: Olympus Raises Colorectal Cancer Awareness Through eBay Giving Works Auction
11. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: